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Abstract
Summary Stopping denosumab after 8 years of continued
treatment was associated with bone loss during a 1-year
observation study in patients who were not prescribed
osteoporosis treatment. Bone loss was attenuated in pa-
t ients who began another osteoporosis therapy.
Treatment to prevent bone loss upon stopping denosumab
should be considered.
Introduction This study aimed to understand osteoporosis
management strategies during a 1-year observational
follow-up after up to 8 years of denosumab treatment in
a phase 2 study.
Methods During the observational year, patients received
osteoporosis management at the discretion of their physi-
cian and returned to the clinic for BMD assessment and
completion of an osteoporosis management questionnaire.
Incidence of serious adverse events and fractures was col-
lected. Analyses were descriptive.
Results Of 138 eligible patients, 82 enrolled in and com-
pleted the observation study. Most (65 [79%]) did not
receive prescription osteoporosis medication, with Bmy
doctor felt I no longer needed a medication^ being the
most common reason (23 [35%]). Of the 17 patients
who took osteoporosis medications, 8 discontinued thera-
py during the observation study. In patients treated with
denosumab for 8 years (N = 52), BMD decreased during
the 1-year observation study (6.7% [lumbar spine], 6.6%
[total hip]). Those who took osteoporosis medication dur-
ing the observation study showed a smaller decline in
BMD than those who did not. No new safety concerns
were identified. Eight patients (9.8%), all of whom had
at least one predisposing risk factor, experienced 17 frac-
tures. This included seven patients who experienced one
or more vertebral fractures.
Conclusions Consistent with denosumab’s mechanism of ac-
tion, treatment cessation led to reversal of the drug’s effect on
BMD and perhaps fracture risk. For patients who took osteo-
porosis therapy, bone loss was attenuated. For patients at high
fracture risk, switching to another osteoporosis therapy if
denosumab is discontinued seems appropriate.
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Introduction
Osteoporosis is a chronic disorder that requires long-term treat-
ment with pharmacologic therapy to ensure sustained anti-
fracture benefit. Due to concerns about rare bone safety events,
including atypical femoral fracture (AFF) and osteonecrosis of
the jaw (ONJ), questions have arisen regarding appropriate
duration of treatment and whether efficacy, safety, and/or
time-dependent thresholds should dictate when to discontinue
therapy [1, 2]. Bisphosphonates have a long terminal half-life
in bone due to affinity to hydroxyapatite, and they are not
metabolized. This has prompted the thinking that stopping ther-
apy for an interval of time, commonly referred to as a Bdrug
holiday,^ could save medical costs while maintaining treatment
benefits for at least some time, particularly in patients no longer
at high risk of fracture [3, 4]. Because of differences in mech-
anisms of action and metabolic clearance among different drug
classes, the concept of a bisphosphonate drug holiday is not
applicable to reversible, non-bisphosphonate treatments, in-
cluding estrogen therapy, estrogen agonists/antagonists (ralox-
ifene, bazedoxifene), parathyroid hormone analogues
(teriparatide, abaloparatide), and the RANKL inhibitor
denosumab. However, there are only limited data showing that
treatment cessation with non-bisphosphonate bone active ther-
apies may not be appropriate [5–10].
Denosumab, a therapy for osteoporosis in men and post-
menopausal women and for bone loss associated with hor-
mone ablation therapy, is a fully human monoclonal antibody
that binds to and inhibits RANKL. Treatment for up to
10 years results in continued gains in lumbar spine and total
hip bone mineral density (BMD) without therapeutic plateau,
with low fracture incidence, and a safety profile that remained
consistent over time [11–15]. Rare cases of femoral fractures
with atypical features (N = 2) and osteonecrosis of the jaw (n =
8) have been observed with denosumab therapy up to 8 years
[14]. The original 4-year denosumab phase 2 dose-ranging
trial was extended to 8 years to understand long-term effects
of continued therapy [16–20]. An additional 1-year observa-
tion study following the end of treatment was conducted to
understand osteoporosis management strategies chosen by cli-
nicians for patients with low bone mass who had received
denosumab for up to 8 years. This report summarizes data
from this final year.
Methods
The methodologies of both the original phase 2 dose-ranging
parent study (years 1–4) and its extension (years 5–8) have
already been published [16–20]. Details of the 1-year obser-
vation study (year 9) following the end of 8 years of
denosumab treatment are described below.
Study design
Postmenopausal women who successfully completed the
8 years of the parent and extension study were eligible to
participate in the observation study. There were no study-
specific medications or supplements administered during the
1-year observation. However, any medication or supplements
could be prescribed at the discretion of the patients’ health
care providers.
Patients were asked to return to the clinic at the end of the
observation study to provide information about osteoporosis
medication management, including incidence, type, and reason
for initiating and stopping prescription osteoporosis drug use
since completing the extension study at the end of year 8
(Supplemental Table 1), and for BMD assessments. Mean per-
centage changes in lumbar spine and total hip BMD during the
observation study were stratified by osteoporosis medication
status. Serious adverse events were recorded, as were clinical
fractures that occurred since the end of treatment at year 8.
During the phase 2 dose-ranging trial, its extension, and the
observation study, spinal radiographs were not routinely obtain-
ed but only at the discretion of the treating clinician. A formal
statistical hypothesis was not tested at the end of this 1-year
observation study. All analyses were descriptive in nature.
The study protocol was reviewed and approved by an in-
stitutional review board at each center, and all women provid-
ed written informed consent. The study was performed in
compliance with the Food and Drug Administration,
International Conference on Harmonisation Good Clinical
Practice guidelines, and the World Medical Association
Declaration of Helsinki principles.
Results
Patient disposition
Of the 200 patients enrolled in the extension study of the phase
2 dose-ranging trial, 138 patients completed the 4-year exten-
sion. Eight-two of those patients, from 13 centers in the USA,
enrolled in the observation study (Fig. 1), all of whom com-
pleted the 1-year study.
Baseline characteristics
Patients enrolled in the observation study were women with a
mean age of 68.9 years (22% were ≥75 years of age) who had
been postmenopausal for an average of approximately
18 years (Table 1). The majority of the patients were
Caucasian (89%); 6.1% were Hispanic. Mean BMD T-scores
at the lumbar spine and total hip were −1.08 and −1.03, re-
spectively, while the average T-scores had been −2.14 and
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−1.44, respectively, 8 years earlier at the beginning of the
phase 2 study.
Osteoporosis medication management
The majority of the 82 patients (65 [79%]) reported that they
did not take prescription medication for osteoporosis during
the observation study. Of these patients, 34 (52%) reported
that their physician had recommended no treatment, with the
most common reason being that the doctor felt that the patient
no longer needed a medication (Supplemental Fig. 1). Most of
the 17 (21%) patients who did take prescriptionmedication for
osteoporosis did so on the recommendation of either the re-
search physician for this study (n = 7) or their personal phy-
sician (n = 6). The following medications were taken by pa-
tients for osteoporosis management: alendronate (seven pa-
tients), denosumab (five patients), risedronate (four patients),
ibandronate (two patients), and teriparatide (two patients)
(Supplemental Fig. 1). Three patients switched osteoporosis
medications during the observational period: one from
alendronate to risedronate due to gastrointestinal AE and then
discontinued due to medication cost, one from alendronate to
ibandronate due to unspecified AE, and one from ibandronate
to teriparatide without specified reason. Eight (47%) of these
17 patients stopped taking their osteoporosis medication dur-
ing the observation study, with most (n = 5) noting side effects
of the medication as the reason. Nine of the 17 patients were
still taking an osteoporosis medication at the end of the 1-year
observation. Daily supplementation of 400–800 IU vitamin D
and at least 500 mg elemental calcium had been required
throughout the treatment phase of the study, and all 82 patients
continued to take both supplements during the observation
study.
Bone mineral density
For patients who received denosumab for 8 years (n = 52) and
those who received placebo for 4 years during the parent study
followed by denosumab for 4 years in the extension study
(n = 10), mean percentage change in BMD was assessed from
phase 2 dose-ranging trial baseline to the end of the 8-year
treatment phase of the extension study (years 1–8), to the end
of the observational year (years 1–9), and from the end of the
extension study to the end of the observational year (year 9).
In the 10 patients who took denosumab during the extension
study (years 5–8) after having received placebo during years
Fig. 1 Design of the parent study,
its extension, and the observation
study. DMAb denosumab, Q3M
once every 3 months, Q6M once
every 6 months, QW once weekly
Table 1 Baseline characteristics
Parent study Extension study Observation study
Years 1–4
Baseline
Years 5–8
Baseline
Year 9
Baseline
All patients
N = 412
Denosumab
N = 319
Denosumab
N = 200
All patients
N = 82
Age, years 62.5 (8.1) 62.3 (8.0) 66.1 (7.7) 68.9 (6.4)
Age ≥ 75 years, n (%) 35 (8.5) 24 (7.5) 29 (14.5) 18 (22.0)
Lumbar spine T-score –2.14 (0.78) –2.14 (0.77) –1.55 (0.96) –1.08 (1.04)
Total hip T-score –1.44 (0.71) –1.42 (0.69) –1.21 (0.73) –1.03 (0.77)
Patients who completed, n (%) 262 (64) 203 (64) 138 (69) 82 (100)
Values are mean (standard deviation) unless indicated otherwise
Osteoporos Int
1–4, BMD decreased but remained above or near their pre-
denosumab treatment values during the observation study
(Fig. 2). The remainder of the discussion of BMD results
focuses on the group that had received 8 years of denosumab
treatment during the phase 2 dose-ranging trial and its exten-
sion because this is the largest cohort (N = 52) that was follow-
ed longitudinally and, therefore, has the least variability in
BMD measurements. After treatment with denosumab for
8 years, the average increases in BMD at the lumbar spine
and total hip were 16.8 and 6.2%, respectively. During the
observation study (year 9), BMD decreased, on average, by
6.7% at the lumbar spine and 6.6% at the total hip (Fig. 2).
Over the full 9-year period, BMD remained above or near the
phase 2 study baseline level at the lumbar spine (+9.1%) and
total hip (−1.0%), respectively.
The changes in BMD during the year 9 observation study
were influenced by osteoporosis medications. For patients
who received denosumab for 8 years during the phase 2 study
and who did not take any prescription medications for osteo-
porosis during the observation study (N = 42), mean BMD
change over the 1-year observation was −7.4% at the lumbar
spine and −7.8% at the total hip (Fig. 3). Compared with their
values at the phase 2 parent trial baseline, the BMD over the 9-
year study period remained above or near level at the lumbar
spine (+8.2%) and total hip (−2.2%), respectively. In contrast,
among the five patients who were taking prescription medica-
tions for osteoporosis at the end of the observation study, the
mean BMD change over the observation study was −2.9% at
the lumbar spine and −2.2% at the total hip (Fig. 3). Decreases
in BMD during year 9 in five patients who took osteoporosis
medications for only part of that year were intermediate
(−4.4% at lumbar spine and −6.1% at total hip) between those
who took medication throughout the year and those who did
not.
Adverse events
During the observation study, a total of nine serious adverse
events were reported in 8 of 82 patients (9.8%; Table 2). No
serious adverse event was reported in more than one patient.
Fig. 2 Percentage change from
phase 2 dose-ranging trial base-
line for a lumbar spine and b total
hip bone mineral density (BMD).
Includes patients who enrolled
into the observation study with
8 years of denosumab (DMAb)
treatment (N = 52) or those with
4 years of placebo followed by
4 years of DMAb treatment
(N = 10). n = number of subjects
with observed BMD at baseline
and year 9. CI confidence inter-
val, LSM least squares mean
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These serious adverse events occurred in one patient each:
aortic stenosis, breast cancer in situ, femoral neck fracture,
lobar pneumonia, non-cardiac chest pain, osteoarthritis, and
benign pituitary tumor. Two serious adverse events (asthenia
and balance disorder) were reported in one patient. No deaths
or withdrawal of patients due to serious adverse events were
reported. There were no serious adverse events of interest
regarding hypocalcemia, ONJ, eczema, skin infection, hyper-
sensitivity, acute pancreatitis, delayed fracture healing, or
atypical femoral fractures.
During the observation study, 8 of 82 (9.8%) patients
experienced at least one fracture (Table 2); a total of 17
fractures were reported. Four patients had multiple verte-
bral fractures, including one with a subsequent femoral
neck fracture, three patients had a single vertebral frac-
ture, and one patient had a radius fracture (Table 3). Since
spine radiographs were not obtained during the 8-year
phase 2 trial, it was difficult to know whether the verte-
bral fractures noted on radiographs during the observation
study were acute or chronic. Of the eight patients who
fractured, six did not take any prescription medication
for osteoporosis during the observation study; the other
two patients began an osteoporosis medication only after
the fracture event. We also are aware of reported vertebral
fracture events after stopping denosumab therapy in two
additional patients who participated in the treatment and
extension components of the phase 2 study but declined to
enroll in the observation study. These two cases are also
included in Table 3.
Discussion
After completing the phase 2 clinical trial during which pa-
tients had received up to 8 years of denosumab treatment,
most patients did not receive any medication for osteoporosis
during the 1-year observation period. Most often, the patient’s
physician had recommended that medication was no longer
required. As is often the case, about half of the patients who
began a prescription medication for osteoporosis after
denosumab discontinuation stopped the therapy during the
1-year follow-up.
The decision by the patient and her personal physician not
to continue therapy may have seemed reasonable since BMD
on denosumab therapy had increased substantially, to average
values well above the indications for treatment. However, un-
like the skeletal effects of bisphosphonates which dissipate
slowly, BMD decreases more quickly upon stopping more
rapidly reversible agents such as estrogen, denosumab, and
odanacatib [18, 21–24]. Consistent with that knowledge,
Fig. 3 Percentage change from observation study baseline in bone
mineral density (BMD) during the 1-year observation study stratified by
postmenopausal osteoporosis (PMO) medication (med) status. Data are
from 52 patients who enrolled into the observation study after 8 years of
continued denosumab treatment. n = number of subjects with observed
BMD at year 8 and year 9. In each box-and-whisker plot, the box repre-
sents the 25th and 75th percentiles, themiddle line represents the median,
and the diamond represents the mean
Table 2 Adverse events during the 1-year observation study
Number of patients (%)
Total patients = 82
Serious adverse events 8 (9.8)
Infectionsa 1 (1.2)
Malignant neoplasmsb 1 (1.2)
Fractures 8 (9.8)
Vertebral 7 (7.3)
Femoral neck 1 (1.2)
Radius 1 (1.2)
Deaths 0
Data are n (%). No patients were reported to have a serious adverse event
of skin infection, eczema, hypocalcemia, hypersensitivity, pancreatitis,
adjudicated positive osteonecrosis of the jaw, atypical femoral fracture,
or delayed fracture healing
a Infection was a lobar pneumonia
bMalignant neoplasm was a breast cancer in situ
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BMD decreased in our patients who stopped denosumab ther-
apy and who did not take other osteoporosis medication. The
rate of bone loss observed in those patients (6–7% in a year)
was similar to that seen in earlier studies, although our patients
had received therapy much longer. This suggests that long-
term denosumab therapy, although resulting in large gains in
BMD, does not protect patients from bone loss when therapy
is discontinued. However, because the patients had experi-
enced such large increases in BMD during the phase 2 trial,
the lumbar spine BMD remained well above the phase 2 trial
baseline 1 year after discontinuation, while the total hip BMD
fell back to the average baseline value.
Taking an osteoporosis medication after stopping
denosumab appeared to attenuate this decline in BMD. This
is consistent with the observation that alendronate prevents
bone loss upon stopping estrogen, parathyroid hormone, or
denosumab therapy [25–27]. In the latter study, postmeno-
pausal women with low bone mass who had received
denosumab for 1 year were switched to weekly alendronate
therapy. The increase in BMD that had occurred with
denosumab therapy was preserved during 1 year of
alendronate therapy.
Eight of the 82 patients (9.8%) experienced one or more
osteoporotic fractures during the 1-year observation study af-
ter stopping denosumab therapy. The incidence of osteoporot-
ic fracture was 4.9% in patients who were receiving
denosumab during years 5–8 of the phase 2 study [20]. All
patients in the observation study who experienced a fracture
had at least one predisposing risk factor for fracture (e.g., prior
fragility fracture, low BMD, advanced age). None of the pa-
tients with fractures had received osteoporosis treatment after
stopping denosumab before their fractures occurred.
There is theoretical concern about a possible increased risk
of fracture upon stopping estrogen or denosumab due to the
rebound in bone turnover to values above pretreatment levels
and the accompanying interval of rapid bone loss [18, 28].
This concern is based on evidence that high bone turnover is
a risk factor for fracture [29]. Protection from fragility frac-
tures appears to persist for at least several months after stop-
ping teriparatide therapy [9, 10]. However, in that setting,
bone turnover decreases upon stopping therapy, in contrast
to the large increase in turnover upon stopping estrogen or
denosumab. Observational studies suggest that fracture risk
increases upon stopping estrogen therapy, but whether there
is an increase in risk above that seen in untreated women
cannot be determined in those studies [5–7]. A careful analysis
of women in theWomen’s Health Initiative (WHI) study dem-
onstrated that hip and vertebral fracture risk after stopping
estrogen therapy quickly returned to but did not rise above
that observed in the group that had received placebo [8].
Fracture incidence after denosumab therapy cessation
has been evaluated in five clinical trials: an earlier part
of this phase 2 dose-ranging study in postmenopausal
women with low bone mass [18], pivotal phase 3 fracture
trial in postmenopausal women with osteoporosis
(Fracture Reduction Evaluation of Denosumab in
Osteoporosis Every 6 Months [FREEDOM] Study [30]),
phase 3 BMD study in postmenopausal women with low
bone mass [23], phase 3 prostate cancer study (Hormone
Ablation Therapy [HALT] Study [31]), and phase 3 breast
cancer study (HALT; [data on file]). While these 5 studies
in 2671 patients do not demonstrate an excess in fracture
risk after discontinuation of denosumab, only the patients
in the FREEDOM study had osteoporosis prior to treat-
ment. In that study by Brown and colleagues [30], the
average duration of denosumab therapy was 3.4 doses
(less than 2 years), and the median follow-up after stop-
ping therapy was 0.8 years (maximum 24 months). In the
327 women who had discontinued denosumab, the inci-
dence of both vertebral fracture and osteoporotic fracture
was lower than that in the 470 women who had
discontinued placebo therapy.
Multiple or severe vertebral fractures occurring soon
after stopping denosumab therapy have recently been de-
scribed in five patients, four of whom had osteoporosis
before treatment, who had received five to six doses of
denosumab [32–34]. Like those patients, most of the ver-
tebral fractures noted during the year of our observation
study occurred within 3 to 4 months of treatment cessa-
tion, that is, 9 to 10 months after receiving their last dose
of denosumab. The incidence of clinical vertebral frac-
tures in our study (7/84 or 8% in 12 months) appears to
be higher than was observed in women discontinuing es-
trogen therapy in the Women’s Health Initiative (WHI)
study (<0.5%) [8]. The women in our study were enrolled
on the basis of low bone mass, which was not the case in
the WHI. All of our patients who experienced vertebral
fractures had a lumbar spine BMD T-score of −2.3 or
lower at the beginning of the phase 2 study. Moreover,
four of the seven patients in the observation study who
experienced vertebral fracture, as well as both of the pa-
tients who were not in the observational study but who
were known to have had a vertebral fracture after stopping
denosumab, had a lumbar spine BMD T-score less than
−2.5 at the phase 2 study baseline. Thus, it is possible that
women in our study who had osteoporosis and the asso-
ciated disruption of trabecular microarchitecture are more
susceptible to vertebral fracture if high bone remodeling
and rapid bone loss occurs upon stopping therapy than
were patients in the WHI study who were generally youn-
ger, had higher bone density, and, probably, better trabec-
ular structure.
Few studies have explored long-term management
strategies in osteoporosis. This study is the first that in-
volves a reversible treatment for osteoporosis. The emer-
gence of rare bone safety concerns—ONJ and AFF—has
Osteoporos Int
prompted the thought that these events may be related to
long treatment duration with bisphosphonates and
denosumab. In many regions, health authorities have up-
dated product labeling for bisphosphonates to encourage
assessment of benefit/risk after 3–5 years of treatment
before consideration of continuing treatment. The impli-
cation (to date unproven) is that a proposed Bdrug holiday
or treatment cessation^ will reduce the risks of ONJ and
AFF. These and other potential rare risks of osteoporosis
medication should not deter clinicians from treating pa-
tients with osteoporosis with an increased fracture risk.
Indeed, in appropriately selected patients, the risk of fra-
gility fracture is far higher than risk of ONJ or AFF, with
the benefits of treatment far outweighing the risks [35].
The results of this study make it clear that a Bdrug
holiday^ or Btreatment cessation^ is not appropriate for
patients with osteoporosis who have been on long-term
denosumab treatment.
We recognize that our study has many limitations, in-
cluding its small size, observational design, the lack of
spinal radiographs prior to and at the end of the study,
and it not being planned to evaluate the effects of therapy
on BMD or fracture risk during the observation study. The
experience described here, however, reinforces our
knowledge that, consistent with the drug’s mechanism of
action, treatment cessation after long-term therapy is as-
sociated with reversibility of the treatment effect, includ-
ing protection from vertebral fracture. The finding of an
increase in fracture risk after stopping denosumab therapy
is not surprising and may be similar to the loss of fracture
protection observed upon stopping estrogen therapy.
Given the small number of patients in our study and the
lack of a control group, the question of whether an inter-
val of excess risk occurs in women with osteoporosis
when denosumab therapy is stopped cannot be answered.
Our results do add to the evidence that transitioning to
another osteoporosis therapy attenuates bone loss upon
stopping denosumab.
Osteoporosis is a chronic condition requiring long-term if
not indefinite treatment, especially in high-risk patients. While
denosumab therapy increases BMD and reduces fracture risk,
the disruption of trabecular architecture caused by osteoporo-
sis is not reversed with treatment. The suggestion of a loss of
fracture protection, which appears as an increase in fracture
frequency after stopping denosumab therapy, is not surprising
given its reversible mechanism and may be similar to the loss
of fracture protection observed upon stopping estrogen thera-
py [8]. There are few reasons to discontinue denosumab ther-
apy. However, if denosumab treatment is discontinued for any
reason, it seems very prudent that therapy with another anti-
remodeling agent, such as a long-acting bisphosphonate,
should be continued in patients at high risk for fracture unless
there is a compelling reason not to do so.
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